Return to sender: Lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis.
Antibodies, Monoclonal, Humanized
/ therapeutic use
Cell Movement
/ immunology
Cholangitis, Sclerosing
/ complications
Gastrointestinal Agents
/ therapeutic use
Gastrointestinal Tract
/ immunology
Humans
Immunologic Factors
/ therapeutic use
Inflammatory Bowel Diseases
/ complications
Liver
/ immunology
T-Lymphocytes
/ immunology
Gut homing
Inflammatory bowel diseases
Integrin alpha4beta7
Sclerosing cholangitis
Vedolizumab
Journal
Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
28
02
2019
revised:
29
04
2019
accepted:
09
05
2019
pubmed:
21
5
2019
medline:
15
12
2020
entrez:
21
5
2019
Statut:
ppublish
Résumé
Primary sclerosing cholangitis (PSC) is an inflammatory disease of the biliary tree, characterised by stricturing bile duct disease and progression to liver fibrosis. The pathophysiology of PSC is still unknown. The concurrence with inflammatory bowel disease (IBD) in about 70% of cases has led to the hypothesis that gut-homing lymphocytes aberrantly traffic to the liver, contributing to disease pathogenesis in patients with both PSC and IBD (PSC-IBD). The discovery of mutual trafficking pathways of lymphocytes to target tissues, and expression of gut-specific adhesion molecules and chemokines in the liver has pointed in this direction. There is now increasing interest in using drugs that intervene with these trafficking pathways (e.g. vedolizumab, etrolizumab) for the treatment of PSC-IBD. In this review we discuss what is currently known about the immunological interactions between the gut and the liver in concomitant PSC and IBD, as well as potential therapeutic options for intervening in these mechanisms.
Identifiants
pubmed: 31108158
pii: S0168-8278(19)30287-9
doi: 10.1016/j.jhep.2019.05.006
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Gastrointestinal Agents
0
Immunologic Factors
0
vedolizumab
9RV78Q2002
etrolizumab
I2A72G2V3J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
603-615Informations de copyright
Copyright © 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.